IL17A and cancer: JQ1, which targets BRD4 and exhibits therapeutic utility in cancer, inhibited the proliferation of keratinocytes and modulated the RORC/IL-17A pathway in a mouse model of psoriasis-like inflammation [69,70,71,72].